Akari Therapeutics(AKTX) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan for Geographic Atrophy Implementation of Restructuring Plan to Reduce Operating Costs Existing Investors Support the Company with Issuance of $1 million in Un ...